Table 1.
Clinical Characteristics of the Two Cohorts
| Variables | Training Cohort | Validation Cohort |
|---|---|---|
| (n=441) | (n=217) | |
| Age | 55.02±10.55 | 54.71±10.05 |
| Sex | ||
| Male | 187 (42.4%) | 35 (16.1%) |
| Female | 254 (57.6%) | 182 (83.9%) |
| Child-Pugh | ||
| A | 235 (53.3%) | 119 (54.8%) |
| B | 206 (46.7%) | 98 (45.2%) |
| HBsAg | ||
| Negative | 400 (46.7%) | 198 (91.2%) |
| Positive | 41 (9.3%) | 19 (8.8%) |
| Hepatocirrhosis | ||
| No | 316 (71.7%) | 159 (73.3%) |
| Yes | 125 (28.3%) | 58 (26.7%) |
| WBC (×109/L) | 5.29 (4.40, 7.20) | 5.15 (4.22, 5.95) |
| GGT (U/L) | 48.50 (28.75, 89.25) | 63.00 (24.75, 104.75) |
| ALP (U/L) | 82.50 (68.00, 102.25) | 91.00 (71.00, 116.5) |
| AST (U/L) | 32.00 (23.00, 54.50) | 29.00 (20.00, 47.25 |
| ALT (U/L) | 31.00 (21.00, 57.25) | 28.50 (19.00, 49.50 |
| AFP (µg/L) | 317.50 (28.00, 2454.00) | 308.80 (16.54, 1794.50) |
| Platelet (×109/L) | 153.00 (112.00, 183.00) | 138.00 (91.00, 165.50) |
| Albumin (g/L) | 40.85 (37.93, 43.25) | 39.00 (35.98, 43.33) |
| Prothrombin time (s) | 11.30 (10.60, 12.20) | 11.110 (10.57, 12.18) |
| Tumor size (cm) | 5.55 (3.50, 7.50) | 5.00 (3.00, 8.00) |
| Monocyte (×109/L) | 0.44 (0.36, 0.63) | 0.46 (0.35, 0.54) |
| Neutrophil (×109/L) | 3.16 (2.45, 4.45) | 2.92 (2.20, 3.77) |
| Lymphocyte (×109/L) | 1.40 (0.99, 1.78) | 1.46 (1.12, 1.81) |
| Total bilirubin (µmol/L) | 12.60 (8.35, 16.44) | 10.60 (7.60, 14.23) |
| GPR | 0.35 (0.20, 0.68) | 0.52 (0.17, 1.02) |
| APR | 0.23 (0.14, 0.42) | 0.24 (0.15, 0.41) |
| GAR | 1.17 (0.68, 2.29) | 1.72 (0.61, 2.64) |
| NLR | 2.17 (1.63, 3.12) | 1.96 (1.43, 3.15) |
| GLR | 37.38 (21.41, 81.31) | 42.94 (16.40, 92.28) |
| ALR | 62.65 (42.72, 95.65) | 58.86 (43.83, 104.60) |
| PLR | 105.44 (77.12, 157.15) | 96.63 (64.72, 123.61) |
| LMR | 3.09 (2.11, 4.17) | 3.25 (2.39, 4.00) |
Abbreviations: WBC, White blood cell; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; GPR, GGT-to-platelet ratio; APR, AST-to-platelet ratio; GAR, GGT-to-albumin ratio; NLR, neutrophil-to-lymphocyte ratio; GLR, GGT-to-lymphocyte ratio; ALR, ALP-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.